期刊文献+

Meta分析:连续性肾替代治疗中枸橼酸抗凝与肝素抗凝方法的比较 被引量:23

Meta analysis:a comparison of methods in CRRT citrate anticoagulation with heparin anticoagulation method
下载PDF
导出
摘要 目的对近年来有关临床随机对照试验结果进行总结,比较连续性肾替代治疗(continuous renal replacement treatment,CRRT)中枸橼酸与肝素抗凝的优劣和安全性。方法对随机对照试验进行系统回顾和荟萃分析。研究对象设定为进入ICU、伴有急性肾损伤和(或)重度脓毒症的患者。研究的选择标准限于随机对照试验研究,对文章的语言不做限制,有入选的非英语文献请专业的机构进行翻译。对CRRT时局部枸橼酸与肝素抗凝进行比较。终点:首要终点是CRRT滤器的使用时间、凝血功能障碍引起的大出血(定义为血压下降或需要≥2个单位的红细胞输注),以及代谢性碱中毒、低钙血症、血小板减少症;次要终点是医疗费用高昂超过患者的负担。结果纳入6个随机对照试验(362例患者)。枸橼酸抗凝是出血减少的影响因素(RR=0.230,95%CI=0.100-0.530),肝素在电解质紊乱和酸碱平衡紊乱方面有着更低的发生率(RR=4.310,95%CI=1.450-12.860),两者在滤器寿命方面差异无统计学意义(95%CI=0.810-1.160),局限性:样本例数不均衡、文献质量不高。结论枸橼酸能够降低抗凝时的出血风险,但会显著增加电解质和代谢异常的发生率。 Objective To analyze recent randomized controlled trials(RCT),to compare the benefit and defect as well as safety of citrate anticoagulation with heparin anticoagulation method in continuous renal replacement treatment(CRRT).Methods A systematic review and Metaanalysis was performed to RCT.Research involved intensive care unit(ICU)admitting patients with acute kidney injury and/or in severe sepsis.Selection criteria included the studies limited to RCT researches,the language did not limit,the non English literature were translated by professionals.Comparison was made in regional citrate anticoagulation with heparin on intervention CRRT.Termination:the primary end points were the time of CRRT filter,major bleeding caused by coagulopathy(defined as a drop in blood pressure or need more than 2 units of red blood cell transfusion)and metabolic alkalosis,hypocalcaemia,thrombocytopenia;secondary end points were the high medical costs more than the burden of patients.Results Six RCT(362 patients)were included.Citrate anticoagulation was a factor to reduce bleeding(RR=0.230,95%CI=0.100-0.530).Heparin had a much lower incidence in the electrolyte imbalance and acid-base balance disorder(RR=4.310,95%CI=1.450-12.860),the two methods showed no significant difference in the life time of filter(95%CI=0.810-1.160).Limitation:the number of sample not balanced and document quality not high.Conclusion Citrate anticoagulation can reduce bleeding risk,but will significantly increase the electrolyte and the incidence of metabolic abnormalities.
出处 《河北医科大学学报》 CAS 2015年第6期644-648,共5页 Journal of Hebei Medical University
关键词 抗凝药 枸橼酸 肝素 META分析 anticoagulants citrate heparin Meta-analysis
  • 相关文献

参考文献16

  • 1To|wani A. Continuous renal-replacement therapy for acute kidney injury[J].N Eng[ J Meal,2012,367(26) :2505-2514.
  • 2Tolwani A, Wille KM. Advances in continuous renal replacement therapy., citrate antlcoagulation update[J3.Blood Purif,2012,34(2) :88-93.
  • 3Lanckohr C, Hahnenkamp K, Boschin M. Continuous renal replacement therapy with regional citrate anticoagulation., do we really know the details? [J]. Curt Opin Anaesthesiol, 2013,26(4) :428-437.
  • 4Oudemans-van Straaten HM,Kellum JA,Bel|omo R.Clinical review: antieoagulation {or continuous renal replacement therapy-hepar[n or citrate? []J. Crlt Care, 2011, 15 (1): 202-210.
  • 5Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin antieoagulation for continuous renal replacement therapy:a meta-analysis of randomized controlled trials~J3. Am J Kidney Dis,2012,59(6) :810-818.
  • 6杨楠,彭民,步怀恩,尹立群,王泓午,窦昊颖.枸橼酸钠用于连续性血液净化抗凝治疗的Meta分析[J].中华肾脏病杂志,2013,29(6):460-462. 被引量:15
  • 7J adad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: Is blinding necessary? [J-1.Control Clin Trials,1996,17(1) :1-12.
  • 8Liberati A, Altman DG~ Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and recta-analyses of studies that evaluate health care interventions: explanation and elaboration[J].J Clin Epidemiol,2009,62(10):el-34.
  • 9Moher D,Cook DJ,Eastwood S,et al.Improving the quality of reports of recta-analyses of randomized controlled trials: the QUOROM statement[J].Br J Surg, 2000,74 (2) : 107- 118.
  • 10DerSimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials, 1986,7 (3) : 177 - 188.

二级参考文献39

  • 1樊蓉,张纯,叶朝阳.高浓度枸橼酸钠注射液在血液透析应用的研究进展[J].中国血液净化,2006,5(4):208-211. 被引量:18
  • 2辛霞,常秀霞,高菊林,杜娟,蒋红利,尹爱萍.连续性血液净化枸橼酸体外抗凝技术在高危出血患者中的应用[J].西安交通大学学报(医学版),2006,27(4):411-413. 被引量:6
  • 3戎殳,叶朝阳,孙丽君,陈静,张斌,梅长林.46.7%枸橼酸钠溶液在血液透析患者长期留置导管封管的应用[J].中华肾脏病杂志,2007,23(2):110-112. 被引量:28
  • 4Uchino S,Bellomo R,Morimatsu H,et al.Continuous renal replacement therapy:a worldwide practice survey.The beginning and ending supportive therapy for the kidney(B.E.S.T.kidney) investigators[J].Intensive Care Med,2007,33(9):1563-1570.
  • 5Kreuzer M,Bonzel KE,Büscher R,et al.Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding[J].Nephrol Dial Transplant,2010,25(10):3337-3342.
  • 6Nedelcu E,Ziman A,Fernando LP,et al.Exclusive use of acid citrate dextrose for anticoagulation during extracorporeal photopheresis in patients with contraindications to heparin:an effective protocol[J].J Clin Apher,2008,23(2):66-73.
  • 7Kutsogiannis DJ,Mayers I,Chin WD,et al.Regional citrate anticoagulation in continuous venovenous hemodiafiltration.Am J Kidney Dis,2000,35:802-811.
  • 8Palsson R,Niles JL.Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.Kidney Int,1999,55:1991-1997.
  • 9Hofmann RM,Maloney C,Ward DM,et al.A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF).Ren Fail,2002,24:325-335.
  • 10Cointault O,Kamar N,Bories P,et al.Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions.Nephrol Dial Transplant,2004,19:171-178.

共引文献33

同被引文献199

  • 1戴铭珠.连续肾脏替代治疗在急危重症中的疗效及护理[J].现代中西医结合杂志,2007,16(26):3888-3889. 被引量:11
  • 2欧阳彬,赖箭波,李小悦,陈娟,管向东,陈敏英,黎丽芬,吴健锋,刘紫锰,杨春华.危重患者连续性肾替代治疗期间的血糖控制策略[J].中国临床营养杂志,2008,16(4):216-219. 被引量:1
  • 3王海涛,毛永辉,李胜利,吴华.枸橼酸-葡萄糖抗凝溶液在高危出血患者连续性血液净化中的应用[J].中华肾脏病杂志,2006,22(3):166-169. 被引量:11
  • 4周薇.不同浓度枸橼酸钠抗凝在连续性肾替代治疗中的作用[J].解放军护理杂志,2007,24(08B):1-3. 被引量:3
  • 5Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: intematlonal guidelines for management of severe sepsis and septic shock :2012 [ J]. Crit Care Med ,2013,41 (2) :580-637.
  • 6Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review :anticoagulation for continuous renal replacement therapy-heparin or citrate? [ J ]. Crit Care,2011,15 ( 1 ) :202-204.
  • 7Wang Y, Ivany JN, Perkovic V, et al. Anticoagulants and antiplatelet a- gents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease [ J ]. Cochrane Database Syst Rev,2016,6 ( 1 ) :67-71.
  • 8Fedotcheva NI, Litvinova EG, Osipov AA, et al. Influence of Microbi- al Metabolites of Phenolic Nature on the Activity of Mitochondrial En- zymes[ J]. Biofizika,2015,60(6) : 1118-1124.
  • 9Sponholz C, Matthes K, Rupp D, et al. Molecular adsorbent recirculat- ing system and single-pass albumin dialysis in liver failure--a pro- spective, randomised crossover study [ J ]. Crit Care,2016,4 ( 1 ) : 2- 6.
  • 10Hanafusa N. Application of continuous renal replacement therapy: what should we consider based on existing evidence? [ J]. Blood Pu- rif,2015,40(4) :312-319.

引证文献23

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部